Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GTAEXS617 phase 1/2 study in advanced solid tumors
2023-508227-13-00Phase 2Suspended
- Sponsor
- Exscientia
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of EXS617 in Nonhematologic neoplasms, ovarian cancer, primary peritoneal cancer (PPC) and 5 more (5 arms), sponsored by Exscientia. Primary endpoints: Incidence of dose-limiting toxicities during cycle 1, Safety and tolerability in Phase 1 and 5 more. Started Jun 2023; status: suspended.
02
Drugs
EXS617
03
Conditions
Nonhematologic neoplasmsovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)breast cancer
Beyond the preview
Go deeper on 2023-508227-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508227-13-00.